Compare Amgen, Inc. (AMGN) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs HubSpot Inc — how do they compare? Amgen, Inc. trades at $416.1 (market cap $224.14B), while HubSpot Inc trades at $208.18 (market cap $11.00B). The key difference: Amgen, Inc. is far larger — about 20.4× HubSpot Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| AMGN | HUBS | |
|---|---|---|
Market Cap | $224.14B | $11.00B |
Sector | Health | Technology |
52-Week High | $417.20 | $522.97 |
52-Week Low | $271.18 | $170.39 |
Enterprise Value | $267.45B | $9.89B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
HubSpot (HUBS) trades at $210.92, down 2.31% on the day, amid a bearish technical signal and recent stock volatility following Q2 2026 results. The company reported strong earnings beats but lowered its customer-growth forecast, contributing to a sharp price decline from previous highs. Revenue growth remains robust at 20% year-over-year, yet high valuation multiples and margin pressures present challenges. Analyst sentiment is predominantly bullish with a $233.93 consensus target, but near-term execution risks and increased AI spending weigh on investor confidence.
The outlook for HUBS hinges on successful execution of its AI-driven strategy amid slower customer acquisition. Investment opportunity lies in its solid revenue growth and market position if it can navigate budget scrutiny and competitive pressures. Key risks include heightened execution risks, potential securities litigation, and the financial impact of strategic shifts, which could limit near-term upside despite long-term transformation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
